VA-CTA
The Consumer Technology Association (CTA)TM hosted the sixth annual CES Unveiled Paris today, making several announcements and shining a spotlight on the latest tech innovation. Co-located for the first time with the Mondial Paris Motor Show , CES Unveiled Paris gathered innovative exhibitors, media and industry professionals to experience the latest tech trends and products expected at CES® 2019 that will change our world for the better. Owned and produced by CTA, CES 2019 will run January 8-11, 2019 in Las Vegas, Nevada.
During the event, CTA Executive Vice President of CES Karen Chupka announced 55 French companies selected as CES® 2019 Innovation Honorees . Selected Honorees included GEOFLEX in the vehicle intelligence and self-driving category and Pixminds honored in the gaming category.
“CES Unveiled Paris highlights the innovative spirit fueling Europe’s dynamic tech market, and the French companies recognized as this year’s CES Innovation Award honorees represent the future of technology,” said Chupka. “The products and services honored today reflect the ingenuity driving our industry forward and improving the way we live, work and play.”
The remaining Innovation honorees will be announced at CES Unveiled New York on November 8, 2018. The full list of Honorees will be posted online at CES.tech and showcased at CES 2019, January 8-11.
CTA President and CEO Gary Shapiro also announced today that Dr. Lisa Su, president and CEO of AMD, will deliver a keynote at CES 2019. Dr. Su joins IBM CEO Ginni Rometty as confirmed CES 2019 keynote speakers, with additional speakers to be announced in the coming weeks.
Showcasing the latest technology products and celebrating European innovation, CES Unveiled Paris was the largest event since its inaugural debut in 2013. The event hosted 1,051 attendees from 44 countries and regions, and featured more than 76 exhibitors.
Now a full-day event, and in collaboration with the Connecting Leaders Club, CES Unveiled Paris debuted the Executive Forum on Innovation, with programming focused on emerging trends including mobility, energy and environment and artificial intelligence. More than 20 speakers were featured, including executives from Axa, Accenture, Google, Salesforce and Valeo, as they discussed the future of innovation, including trends expected at CES this January.
CES 2019 is the world’s most important and influential event. The 2019 event will showcase life-changing technology across every major industry, featuring 4,500 exhibitors across 2.75M net square feet (260K net square meters) of exhibit space. CES provides access to the very latest transformative tech such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, sports, machine intelligence and more.
CES is also one of the largest displays of vehicle technology in the world and was recently named as USA Today’s 10 Best Auto Shows. The 2019 show will feature more than 150 vehicle tech companies, including eight automakers, featuring the latest concept cars and connected vehicles.
Areas new to CES 2019 include the Tourism Marketplace, as well as the recently announced Resilience area, focused on technologies that keep the world healthy, safe, warm, fed and secure in the face of adversity.
Registration for CES 2019 is now open. For the latest exhibitor news and show announcements, visit CES.tech .
High-definition video b-roll of CES is available for easy download on CESbroll.com . See exclusive photos from the CES show floor, keynotes, conference sessions, events and award ceremonies in the CES photo gallery .
About CES:
CES® is the world's gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for 50 years-the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the industry. Owned and produced by the Consumer Technology Association (CTA)TM , it attracts the world's business leaders and pioneering thinkers. Check out CES video highlights . Follow CES online at CES.tech and on social .
About Consumer Technology Association:
Consumer Technology Association (CTA)™ is the trade association representing the $377 billion U.S. consumer technology industry, which supports more than 15 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best-known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.
UPCOMING EVENTS
-
Innovate
Celebrate
- Register
October 15-17, Boston, MA -
CES
Unveiled New York
November 8, New York, NY -
CES
Unveiled Las Vegas
January 6, Las Vegas, NV -
CES
2019
- Register
January 8-11, Las Vegas, NV -
CES
Asia 2019
June 11-13, Shanghai, China
View source version on businesswire.com: https://www.businesswire.com/news/home/20181003005856/en/
Contact:
Consumer Technology Association Teresa Hsu, 703-907-5259 thsu@CTA.tech www.CES.tech or Justin Siraj, 703-907-7415 jsiraj@CTA.tech www.CES.tech
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom